abstract |
According to the present invention, highly effective combinations of PI3K delta and / or CD20 mediated diseases and disorders and compounds of formula (A) (PI3K delta selective inhibitor) antagonist CD20 antibodies are provided for alleviation. In particular, the combination can be used to treat cancer and autoimmune diseases. More specifically, the present invention provides a combination of a compound of formula (A), or a stereoisomer thereof, and yublituximab, for the treatment and / or alleviation of blood cancer such as blood cancer such as leukemia and lymphoma. |